New Data Bolsters Cosentyx In AS & PsA; Humira Head-To-Head Planned
Novartis AG has unveiled fresh data supporting the efficacy of its Cosentyx (secukinumab) drug in ankylosing spondylitis and psoriatic arthritis along with plans to compare that front-running anti-IL-17A agent against AbbVie Inc.'s anti-TNF competitor Humira (adalimumab) in head-to-head clinical trials.
You may also be interested in...
Data showing Novartis' Cosentyx maintained high levels of skin clearance in psoriasis patients along with a favorable safety profile after four years should give the drug an advantage over new interleukin inhibitors undergoing Phase III trials in psoriasis.
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.